Voyager Therapeutics, Inc. - Common Stock (VYGR)

Voyager's Alzheimer's programs show longer CNS exposure and potential gene therapy advances, with analysts maintaining a Buy rating and $30 price target.

Should you consider VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) for growth investing?

High growth, ROE and relative strength for VOYAGER THERAPEUTICS INC (NASDAQ:VYGR), growth investors may appreciate this.

The article outlines three high-growth stocks that could double by 2025, using specific screening criteria: strong buy ratings from multiple analysts, significant revenue and earnings growth, and substantial recent earnings surprises.

Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks.

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

VYGR stock results show that Voyager Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.

Why VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) qualifies as a high growth stock.

VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) may be suited for growth investing, we'll explore why in this article.

With so many thousands of securities available, there are bound to be compelling ideas for value stocks under $20.

Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term value.

Unlocking the Growth Potential of VOYAGER THERAPEUTICS INC (NASDAQ:VYGR).